Direct compression of standardized milk thistle extract is governed by the powder rheology of the dried extract rather than by silymarin assay alone. The native spray-dried or vacuum-dried extract is typically a low-density, cohesive powder with a median particle size of 80–150 µm, a Hausner ratio above 1.30, and a compressibility index above 25% when tested by USP <1174>; this places the material outside the direct compression flow envelope unless a highly compactable filler and a glidant are employed. Compliance for oral tablet manufacture is based on 21 CFR 210/211, ICH Q7, USP <905> for dose uniformity, USP <701> for disintegration, USP <711> for dissolution, and USP <1216> for friability; where the dosage form is filed in the European Economic Area, Ph. Eur. 2.9.40, 2.9.1, and 2.9.3 serve as parallel reference methods. A representative 420 mg core comprises 140 mg extract (33.3% w/w), 252 mg microcrystalline cellulose PH102 (60.0% w/w), 16.8 mg croscarmellose sodium (4.0% w/w), 8.4 mg colloidal silicon dioxide (2.0% w/w), and 2.8 mg magnesium stearate (0.67% w/w). Process operations include pre-sieving through a 600 µm mesh, dry blending in a 600 L bin blender at 8–10 rpm for 20 min, lubrication for 3 min, and compression on a 27-station rotary tablet press fitted with 8.5 mm round biconcave tooling at 10–14 kN force; tablet hardness is maintained at 90–120 N, friability below 0.8% w/w, and disintegration below 15 min. Because the extract becomes tacky above 55% RH, the compression suite is maintained at 25 ± 2 °C and 30–40% RH. Terminal product type: immediate-release film-coated oral tablet containing 140 mg standardized extract per core.

Why Does Roller Compaction Improve Capsule Fill Uniformity at 140 mg Extract Load?

Capsule fill weight variability at 140 mg extract load is the primary reason roller-compacted granules are used before encapsulation; direct filling of the 80–150 µm extract can exceed ±5% weight variability due to low bulk density, electrostatic charging, and dust losses. Roller compaction produces densified granules with a mean particle size of 300–500 µm and bulk density of 0.55–0.70 g/mL, which permits consistent filling on dosator-type machines. Compliance for hard gelatin or HPMC capsules is drawn from 21 CFR 211.110 for in-process sampling, USP <905> for weight variation, USP <701> for capsule disintegration, USP <711> for dissolution in validated medium, and ICH Q3D for elemental impurities; capsule moisture content is controlled below 3.0% by Karl Fischer because no preservative is used. The dry-granulated blend is formulated at 50–60% w/w extract, 25–35% w/w microcrystalline cellulose PH101, 5–8% w/w crospovidone, 1.0–2.0% w/w colloidal silicon dioxide, and 0.5–1.0% w/w sodium stearyl fumarate. For a 140 mg extract dose, fill weight is 250–280 mg at 53% w/w extract loading. Roller compaction is operated at roll pressure 4–6 kN/cm, roll gap 1.5–2.0 mm, roller speed 4–8 rpm, and the compacted ribbons are screened through 1.0 mm; the granules are blended for 15 min and filled on a dosator-type capsule filler at 30,000–45,000 capsules/h with a fill weight rejection limit of ±3.0%. Magnesium stearate is avoided above 1.0% w/w because higher levels delay dissolution. Terminal product type: hard gelatin or HPMC capsules containing 140 mg standardized extract as dry-granulated blend.

Wet Granulation Parameters for Milk Thistle Extract Multi-Particulate Sachets

In the manufacture of single-dose oral granules, wet granulation is selected when direct compression cannot satisfy sieve-fraction uniformity and when rapid redispersion in water is required. The extract is first pre-blended with mannitol, crospovidone, and povidone K30; the compliance framework includes ICH Q7, 21 CFR 210/211, USP <61>/<62> for microbial limits, USP <1174> for flow, USP <786> for particle size estimation, and ICH Q3C for residual ethanol if hydro-alcoholic granulation is used. The formulation addition ratio is 25–35% w/w extract, 50–65% w/w mannitol SD 100, 3–5% w/w povidone K30, 2–4% w/w crospovidone XL, and 0.5–1.0% w/w colloidal silicon dioxide. The binder solution is prepared at 15% w/w povidone in purified water and added at 20–33% w/w of dry powder mass. In a high-shear granulator, impeller speed 200–250 rpm and chopper 1,500 rpm are maintained for 3–5 min; the wet mass is passed through a 1.2 mm sieve, dried in a fluid-bed dryer with inlet air at 50–60 °C, bed temperature 35–40 °C, and final moisture below 3.0% w/w by USP <921>. The dried granules are sized through a 0.8 mm sieve and filled at 500 mg per sachet to deliver 140 mg extract; fill weight checkweighing rejects sachets outside ±2.0%. Strong alkali is not added to the binder solution because silymarin undergoes ring-opening degradation at pH above 9. Terminal product type: single-dose foil-laminated sachet granules for oral suspension, dispersible in 50–100 mL water before administration.

Native silymarin is practically insoluble in water at neutral pH; therefore, an injectable presentation cannot be prepared by simple dissolution of the standardized dry extract. Injectable products based on milk thistle active constituents use a water-soluble silibinin derivative, such as silibinin disuccinate sodium, which is produced by chemical derivatisation of silybin A/B and is not equivalent to the unprocessed extract. Compliance for sterile solution manufacture includes EU GMP Annex 1, 21 CFR 210/211, USP <1> for injections, USP <71> for sterility, USP <85> for bacterial endotoxins, USP <788> for particulate matter, ICH Q3D for elemental impurities, and ISO 13408-1:2008 for aseptic processing. A marketed sterile configuration contains 528.5 mg silibinin disuccinate sodium per vial, equivalent to 350 mg silibinin; the powder is reconstituted with 35 mL water for injection to yield 10 mg/mL silibinin equivalent before dilution in 0.9% saline or 5% glucose to 1–2 mg/mL for infusion. This is cited as a reference configuration, not a bioequivalence statement. The bulk solution for aseptic filling is compounded at 10 mg/mL silibinin equivalent, corresponding to approximately 15.1 mg/mL of the disuccinate sodium salt, or 1.51% w/v; if mannitol is added at 40 mg/mL, total solid content before lyophilization is 5.5% w/v. The sterile manufacturing process requires dissolution of the derivative in cold 4–8 °C water for injection, pH adjustment to 7.0–7.5 with dilute sodium hydroxide, sterile filtration through 0.22 µm PVDF or PES membrane qualified for bacterial retention per ASTM F838-20, aseptic filling into Type I borosilicate glass vials, and terminal inspection for particulates. Native extract is incompatible with simple aqueous injection due to precipitation and high particulate load; autoclaving is not acceptable because flavonolignans are susceptible to oxidative degradation, so aseptic processing is specified. Terminal product type: sterile injectable solution or sterile powder for injection after reconstitution.

When Lyophilized Silibinin Disuccinate Sodium Requires Collapse-Free Freeze-Drying

During freeze-drying of silibinin disuccinate sodium, the glass transition temperature of the maximally freeze-concentrated amorphous phase defines the maximum allowable product temperature before the cake collapses, shrinks, or increases reconstitution time beyond the label claim. Compliance for the lyophilization process includes EU GMP Annex 1, 21 CFR 210/211, ICH Q2(R2) for analytical validation, ICH Q3D for elemental impurities, USP <71> for sterility, USP <85> for bacterial endotoxins, USP <788> for particulate matter after reconstitution, and USP <921> for moisture. The formulation addition ratio in the dry product is dominated by the drug salt; bulking agent mannitol is employed at 10–20% w/w of the dry cake mass, and residual moisture is specified at ≤ 2.0% w/w. Published data for the specific collapse temperature of silibinin disuccinate sodium formulations is limited; therefore, freeze-drying microscopy and differential scanning calorimetry are used to establish the product temperature limit. A representative but non-universal cycle for a 10 mg/mL silibinin equivalent solution includes freezing to −40 °C at 0.5 °C/min, primary drying at shelf temperature −10 °C and chamber pressure 0.20 mbar for 24 h, and secondary drying at 25 °C and 0.05 mbar for 12 h. The product temperature is controlled below the collapse temperature by adjusting shelf ramp and chamber pressure; batch failures on production lines are commonly caused by vial bottom temperature variation across a 12 m² freeze-dryer shelf array. After cycle completion, vials are stoppered under dry nitrogen and crimp-sealed. Terminal product type: sterile lyophilized powder for reconstitution, intended for intravenous infusion after dilution.